×
Rafael Holdings Total Long Term Liabilities 2017-2025 | RFL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Rafael Holdings total long term liabilities from 2017 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.
View More
Rafael Holdings Total Long Term Liabilities 2017-2025 | RFL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Rafael Holdings total long term liabilities from 2017 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$81.7B
Zoetis (ZTS)
$67.1B
Daiichi Sankyo, - (DSNKY)
$46.4B
Takeda Pharmaceutical (TAK)
$45.5B
BeOne Medicines - (ONC)
$32.3B
Sandoz Group AG (SDZNY)
$26.1B
Summit Therapeutics (SMMT)
$20.4B
Merck (MKKGY)
$16.9B
Shionogi (SGIOY)
$15B
United Therapeutics (UTHR)
$13.4B
Neurocrine Biosciences (NBIX)
$13.2B
Orion OYJ (ORINY)
$11.5B
IPSEN (IPSEY)
$10.8B
Stevanato Group S.p.A (STVN)
$7.9B
Corcept Therapeutics (CORT)
$7.3B
Grifols, S.A (GRFS)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.6B
Madrigal Pharmaceuticals (MDGL)
$6.5B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.3B
Hypermarcas (HYPMY)
$3B
Crinetics Pharmaceuticals (CRNX)
$2.8B
NewAmsterdam Pharma (NAMS)
$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2B
Ocular Therapeutix (OCUL)
$1.9B
Endo (NDOI)
$1.8B
ARS Pharmaceuticals (SPRY)
$1.8B